Target Name: MIR1236
NCBI ID: G100302242
Review Report on MIR1236 Target / Biomarker Content of Review Report on MIR1236 Target / Biomarker
MIR1236
Other Name(s): MicroRNA 1236 | hsa-miR-1236-5p | MIRN1236 | hsa-mir-1236 | microRNA 1236 | hsa-miR-1236-3p

MIR1236: A Potential Drug Target and Biomarker

Mir1236, a protein expressed in human placenta, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique expression pattern and structural features make it an attractive target for small molecule inhibitors. In this article, we will discuss the research on MIR1236, its potential drug targeting, and its role as a biomarker in disease diagnosis and treatment.

MIR1236: A Placenta-Specific Protein

MIR1236 is a 123-kDa protein that is expressed in the placenta, a vital organ that supports the development and maintenance of fetal tissues. The placenta plays a critical role in providing nutrients and oxygen to the developing fetus while removing waste products and other substances from the body. MIR1236 is one of the many proteins that are expressed in the placenta and has been identified as a potential drug target due to its unique expression pattern and structural features.

Potential Drug Target

MIR1236 has been selected as a potential drug target due to its involvement in various physiological processes that are important for human health. One of the key functions of MIR1236 is its role in cell signaling, particularly in the regulation of cell adhesion and migration. MIR1236 has been shown to play a critical role in the development and maintenance of neural stem cells and has been linked to various neurological disorders, including cancer.

In addition to its role in cell signaling, MIR1236 has also been shown to play a key role in the regulation of inflammation and immune responses. MIR1236 has been shown to be involved in the regulation of T cell responses and has been linked to various autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

Biomarker Potential

MIR1236 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique expression pattern and structural features make it an attractive target for small molecule inhibitors. By inhibiting the activity of MIR1236, researchers hope to develop new treatments for these diseases.

One of the key challenges in developing new treatments for diseases is identifying reliable biomarkers that can be used to monitor disease progress and response to treatment. MIR1236 has been shown to be an attractive biomarker for a variety of diseases due to its unique expression pattern and structural features. By using techniques such as qRT-PCR, Western blotting, and immunofluorescence, researchers have been able to validate the potential of MIR1236 as a biomarker for cancer, neurodegenerative disorders, and autoimmune diseases.

Conclusion

MIR1236 is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique expression pattern and structural features make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the role of MIR1236 in these diseases and to develop new treatments based on its unique properties. By studying MIR1236 and its potential drug targeting and biomarker properties, researchers hope to make significant contributions to the development of new treatments for a variety of diseases.

Protein Name: MicroRNA 1236

The "MIR1236 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1236 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305